Genetically Engineered Plant Allergens with Reduced Anaphylactic Activity
- 1 June 1999
- journal article
- review article
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 119 (2), 75-85
- https://doi.org/10.1159/000024181
Abstract
Allergy immunotherapy is based on the administration of increasing amounts of the disease–eliciting allergens in order to yield allergen–specific non–responsiveness. Success of this therapy is associated with modulation of the immune response to allergenic molecules at the level of T–helper cells and the induction of blocking antibodies. The extracts used for immunotherapy are highly heterogenous preparations from natural sources and contain additional components, mostly proteins which are not well defined. Recombinant DNA technology offers novel tools for production of pure and well–characterised allergens for specific immunotherapy. However, high IgE reactivity of pure recombinant allergens is associated with an increased risk of potentially life–threatening anaphylactic reactions. A major improvement in allergen–specific immunotherapy may be achieved by using genetically engineered recombinant allergens with reduced anaphylactic activity. Recently the site– directed mutagenesis technique has been applied successfully to produce variants of major grass, birch and oilseed rape allergens with reduced IgE reactivity but retained T–cell reactivity. These modified allergens with reduced anaphylactic potential are novel candidates for safer and more effective allergen–specific immunotherapy.Keywords
This publication has 13 references indexed in Scilit:
- Calcium–Binding Allergens: From Plants to ManInternational Archives of Allergy and Immunology, 1998
- Ole e 3, An Olive‐Tree Allergen, Belongs to a Widespread Family of Pollen ProteinsEuropean Journal of Biochemistry, 1996
- Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for immunotherapy.The Journal of Experimental Medicine, 1996
- Isoforms of Bet v 1, the Major Birch Pollen Allergen, Analyzed by Liquid Chromatography, Mass Spectrometry, and cDNA CloningJournal of Biological Chemistry, 1995
- Immunotherapy with allergensPublished by American Medical Association (AMA) ,1992
- PCR based cloning and sequencing of isogenes encoding the tree pollen major allergen Car b I from Carpinus betulus, hornbeamMolecular Immunology, 1992
- Induction of TH1 and TH2 responses: a key role for the ‘natural’ immune response?Immunology Today, 1992
- Cloning sequencing of Lol pI, the major allergenic protein of rye‐grass pollenFEBS Letters, 1991
- Intracellular calcium-binding proteins: more sites than insightsTrends in Biochemical Sciences, 1991
- Isolation and characterization of a major cross-reactive grass group I allergenic determinantMolecular Immunology, 1989